COPD

More in COPD

• Bad air quality in Delhi spiking asthma, lung problems in kids, elderly

  The continuing air pollution levels in the national capital is increasing asthma and lung problems in children and the elderly, doctors said on Wednesday.

  

• Global Hospitals unveils advanced respiratory care unit

  The country has witnessed a noticeable uptick in the prevalence of respiratory ailments. Among them, one specific type of pulmonary issue that has been on the rise is chronic obstructive pulmonary disease (COPD), encompassing conditions like chronic bronchitis and emphysema. The factors contributing to the rising rates of COPD include smoking, air pollution, exposure to second-hand smoke, and genetic predisposition.

  

• People with lung conditions face more risks from climate change: Study

  The findings of the research published in the European Respiratory Journal. The study puts together evidence on how the effects of climate change, including as heatwaves, wildfires, and flooding, would increase breathing difficulties for millions of people worldwide, particularly newborns, young children, and the elderly.

  

• Lupin joins hands with entities to expand access to medication for COPD patients in US

  The COPD Foundation is a not-for-profit organisation established to improve the lives of people with COPD (chronic obstructive pulmonary disease), bronchiectasis, and Nontuberculous Mycobacterial (NTM) lung disease. The collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US, Lupin said in a statement.

  

• Lupin subsidiary in Australia gets approval to market asthma drug

  Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsules for use with LupinHaler is indicated for the long-term maintenance treatment of bronchospasm and dyspnea associated with chronic obstructive pulmonary disease (COPD) and for the prevention of COPD exacerbations.

  

• TGA Australia approves Lupin’s Tiotropium dry powder for inhalation in COPD treatment

  Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsules for use with LupinHaler is indicated for the long-term maintenance treatment of bronchospasm and dyspnea associated with chronic obstructive pulmonary disease (COPD) and for the prevention of COPD exacerbations.

  

• Researchers find dupilumab reduces disease in COPD patients with type 2 inflammation

  COPD patients often have markedly reduced lung function and an increased risk of exacerbations, indicated by worsening cough and labored breathing or an increased volume of purulent sputum. Disease exacerbations can lead to an increased risk of subsequent exacerbations, accelerated lung-function decline and an increased risk of death.

  

• Lupin Human Welfare and Research Foundation, Maharashtra Government sign MoU to address growing CVD, COPD prevalence

  The programme will be implemented over the next five years, initially focusing on two blocks, Palghar and Dahanu. The primary objectives include raising awareness about the risks associated with CVD and COPD, highlighting the importance of early screening, and diagnosis to prevent complications and decrease mortality rates.

  

• Study that links mucus plugs to COPD mortality could save lives

  COPD affects 15.9 million people in the United States and is the fourth leading cause of death. It most often occurs as a result of cigarette smoking or long-term exposure to air pollutants.

  

• Continuous, more precise, remote health monitoring is the way of the future in healthcare:Pankaj Balwani, Xplore Lifestyle

  Medical IoT is currently valued at around $22 billion. The big sector is opening up with a much bigger and at least 10 times higher application that has to do with continuous patient monitoring. Based on this medical data, valuable lives can be saved in the case of any disability that can be prevented.

  

• Respiratory infections in a child could lead to death as an adult: Study

  The first-of-its-kind study spanning over seven decades suggests that people who had a lower-respiratory-tract infection (LRTI), such as bronchitis or pneumonia, by the age of two were 93% more likely to die prematurely from respiratory disease as adults, regardless of the socioeconomic background or the smoking status.